Fluconazole is not inferior than caspofungin, micafungin or amphotericin B in the presence of 50% human serum against Candida albicans and Candida parapsilosis biofilms
Authors:
- 18 October 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 57 (5) , 573-581
Abstract
Biofilm formation is a relevant risk factor for mortality in candidemia. Data about serum-based susceptibility testing against Candida biofilms are scant; therefore, the activity of fluconazole, amphotericin B, caspofungin and micafungin was determined against Candida albicans and C. parapsilosis biofilms with or without 50% human serum using XTT-based assays. Serum caused a remarkable adverse effect regarding biofilm structure for both species. Additionally, the ratio of nonviable cells increased for C. parapsilosis biofilms, as confirmed by fluorescent microscopy and flow cytometry. Despite impaired biofilm development, traditionally biofilm-active antifungals, surprisingly, showed decreased activity against C. albicans biofilms in serum at concentrations ranging from 0.5 to 1 mg/l and from 0.015 to 1 mg/l for amphotericin B and echinocandins, respectively (P < .01–.05). However, C. parapsilosis showed higher susceptibility to these antifungals due to reduced biofilm mass and the fungicidal effect of serum at concentrations ranging from 0.015 to 1 mg/l and from 0.015 to 512 mg/l for amphotericin B and echinocandins, respectively (P < .01–.05). Fluconazole exerted better antifungal activity in serum than traditionally biofilm-active antifungals against both examined biofilms. For fluconazole, significant differences were observed in susceptibility between serum-treated and serum-free biofilms at concentrations ranging from 0.015 to 8 mg/l and from 0.03 to 512 mg/l for C. albicans and C. parapsilosis isolates, respectively (P < .01–.05). The high antifungal activity of fluconazole in 50% serum both against C. albicans and C. parapsilosis biofilms supports the utility of fluconazole prophylaxis to reduce the risk of catheter-associated fungal infections.Keywords
Funding Information
- Astellas Phamra Inc.
This publication has 32 references indexed in Scilit:
- Species-Specific and Drug-Specific Differences in Susceptibility of Candida Biofilms to Echinocandins: Characterization of Less Common Bloodstream IsolatesAntimicrobial Agents and Chemotherapy, 2013
- Progress in Antifungal Susceptibility Testing of Candida spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012Journal of Clinical Microbiology, 2012
- Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteriaDrug Resistance Updates, 2011
- Echinocandin Antifungal Drugs in Fungal InfectionsDrugs, 2011
- Pharmacokinetics, Safety, and Tolerability of Caspofungin in Children and AdolescentsAntimicrobial Agents and Chemotherapy, 2005
- Candida orthopsilosis and Candida metapsilosis spp. nov. To Replace Candida parapsilosis Groups II and IIIJournal of Clinical Microbiology, 2005
- Antifungal Susceptibility ofCandidaBiofilms: Unique Efficacy of Amphotericin B Lipid Formulations and EchinocandinsAntimicrobial Agents and Chemotherapy, 2002
- Clinical Pharmacokinetics of FluconazoleClinical Pharmacokinetics, 1993
- Serum fungistatic and fungicidal activity in volunteers receiving antifungal agentsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1986
- Factors affecting the in-vitro adherence of Candida albicans to acrylic surfacesArchives of Oral Biology, 1980